Research And Development Tenders

Drug Discount Contracts with Membership Option - 0065-Rvbeitr.64-2023

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for Medicines with the Active Ingredient Budesonide (Excluding Inhalants) (Atc Code: A07ea06).

Conclusion of a Non-Exclusive Framework Contract for Structural Testing According to Din 1076 in the Open House Procedure of the West Branch, Published in 2023

Medicines with the Active Ingredient Golimumab (Atc: L04ab06)

Medicines with the Active Ingredient Infliximab - in the Dosage Form Powder (Atc:L04ab02)

Completion of a Non-Exclusive Discount Contract According to Section 130A Paragraph 8 Sgb V for Tamoxifen, Atc Code: L02ba01 for the Period from November 1St, 2023 to October 31St, 2025

Conclusion of a Non-Exclusive Framework Agreement for Investigations and Assessments in the Open House Procedure of the West Branch

Completion of a Non-Exclusive Discount Contract According to Section 130A Paragraph 8 Sgb V for Tocilizumab, Atc Code: L04ac07 for the Period from November 1St, 2023 to October 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for Drugs with the Active Ingredient Certolizumab Pegol (Atc Code: L04ab05).

Open House Discount Contracts 2023-07